COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
COMPASS Pathways is motivated by the need to find better ways to help and empower people who are suffering with mental health challenges.
COMPASS Pathways was founded in 2016 by George Goldsmith, Ekaterina Malievskaia and Lars Christian Wilde. The company is headquartered in London, United Kingdom.
COMPASS Pathways' first major initiative is developing psilocybin therapy for treatment-resistant depression (TRD). The company is currently running the world’s first large-scale psilocybin therapy clinical trial, in 20 sites across Europe and North America.
Compass is advancing the clinical program while also working on earlier-stage projects. The biotech initially focused on psilocybin therapy in the belief it could leverage existing knowledge of the drug to quickly get a new product to patients with treatment-resistant depression.
COMPASS Pathways is backed by ATAI Life Sciences, McQuade Center for Strategic Research and Development, Founders Fund, Able Partners, Camden Partners Nexus and others. The company raised $80M in a Series B round on Apr 27, 2020. This brings COMPASS' total funding to $116.2M to date.
